The standard monitoring protocol consists of a PSA test every three months, digital rectal examination twice a year and a prostate biopsy one year after diagnosis and every two or three years thereafter. Annual imaging with a 3-Tesla endorectal MRI or a Color Doppler Ultrasound is also prudent. Some also undergo PCA-3 urinary testing once a year. While on observation many men modify their diet and exercise habits. Mild suppressive treatment with a 5-alpha reductase inhibitor such as finasteride or dutesteride can be considered.
Active surveillance is not a commitment to forgo treatment. It is a commitment to monitor closely and intervene at the first sign of growth or change in the cancer. Close observation over time is the best way to distinguish men who can be safely watched from the men who genuinely need treatment.
Low Risk (Sky)